MYGN Stock Recent News

Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.

Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.

The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Myriad Genetics, Inc. (NASDAQ:MYGN ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Matt Scalo - Senior Vice President, Investor Relations Paul Diaz - President and Chief Executive Officer Mark Verratti - Chief Commercial Officer Bryan Riggsbee - Chief Financial Officer Conference Call Participants Elizabeth Koslosky - Goldman Sachs Andrew Cooper - Raymond James Daniel Sammarco - TD Cowen Jack Meehan - Nephron Research Wolf Chanoff - Bank of America Matt Scalo Good afternoon and welcome to Myriad Genetics Third Quarter 2023 Earnings Call. During the call, we will review the financial results we released today.

SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT. The company's quarterly earnings will be released the same day after the market closes.

Myriad Genetics (MYGN) achieves significant milestones in its partnership with Illumina.

Myriad Genetics (MYGN) announces a collaboration with Memorial Sloan Kettering Cancer Center to study the use of MRD testing in breast cancer.

Investors are optimistic about Myriad Genetics (MYGN) on improvement in testing volume across all its businesses.

Myriad Genetics is a leading molecular diagnostic company that focuses on developing and marketing predictive, personalized, and prognostic medicine tests. The company's financial metrics show multi-faceted performance, with revenue growth, strong gross margins, and prudent cost management. MYGN offers a range of innovative products but faces challenges such as validation and acceptance, accessibility and affordability, and regulatory requirements.

SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept.